دورية أكاديمية
أعرض في EDS

Glucoregulatory Properties of a Protein Hydrolysate from Atlantic Salmon ( Salmo salar ): Preliminary Characterization and Evaluation of DPP-IV Inhibition and Direct Glucose Uptake In Vitro.

التفاصيل البيبلوغرافية
العنوان: Glucoregulatory Properties of a Protein Hydrolysate from Atlantic Salmon ( Salmo salar ): Preliminary Characterization and Evaluation of DPP-IV Inhibition and Direct Glucose Uptake In Vitro.
المؤلفون: Bjerknes C; Hofseth Biocare ASA, Keiser Wilhelms Gate 24, 6003 Ålesund, Norway., Wubshet SG; Nofima AS, Osloveien 1, 1433 Ås, Norway., Rønning SB; Nofima AS, Osloveien 1, 1433 Ås, Norway., Afseth NK; Nofima AS, Osloveien 1, 1433 Ås, Norway., Currie C; Hofseth Biocare ASA, Keiser Wilhelms Gate 24, 6003 Ålesund, Norway., Framroze B; Hofseth Biocare ASA, Keiser Wilhelms Gate 24, 6003 Ålesund, Norway., Hermansen E; Hofseth Biocare ASA, Keiser Wilhelms Gate 24, 6003 Ålesund, Norway.; Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Larsgårdsvegen 2, 6009 Ålesund, Norway.
المصدر: Marine drugs [Mar Drugs] 2024 Mar 28; Vol. 22 (4). Date of Electronic Publication: 2024 Mar 28.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101213729 Publication Model: Electronic Cited Medium: Internet ISSN: 1660-3397 (Electronic) Linking ISSN: 16603397 NLM ISO Abbreviation: Mar Drugs Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2003]-
مواضيع طبية MeSH: Dipeptidyl-Peptidase IV Inhibitors*/pharmacology , Dipeptidyl-Peptidase IV Inhibitors*/isolation & purification , Dipeptidyl-Peptidase IV Inhibitors*/chemistry , Protein Hydrolysates*/pharmacology , Protein Hydrolysates*/chemistry , Salmo salar* , Glucose*/metabolism, Animals ; Humans ; Dipeptidyl Peptidase 4/metabolism ; Hypoglycemic Agents/pharmacology ; Hypoglycemic Agents/chemistry ; Fish Proteins/pharmacology
مستخلص: Metabolic disorders are increasingly prevalent conditions that manifest pathophysiologically along a continuum. Among reported metabolic risk factors, elevated fasting serum glucose (FSG) levels have shown the most substantial increase in risk exposure. Ultimately leading to insulin resistance (IR), this condition is associated with notable deteriorations in the prognostic outlook for major diseases, including neurodegenerative diseases, cancer risk, and mortality related to cardiovascular disease. Tackling metabolic dysfunction, with a focus on prevention, is a critically important aspect for human health. In this study, an investigation into the potential antidiabetic properties of a salmon protein hydrolysate (SPH) was conducted, focusing on its potential dipeptidyl peptidase-IV (DPP-IV) inhibition and direct glucose uptake in vitro. Characterization of the SPH utilized a bioassay-guided fractionation approach to identify potent glucoregulatory peptide fractions. Low-molecular-weight (MW) fractions prepared by membrane filtration (MWCO = 3 kDa) showed significant DPP-IV inhibition (IC 50 = 1.01 ± 0.12 mg/mL) and glucose uptake in vitro ( p ≤ 0.0001 at 1 mg/mL). Further fractionation of the lowest MW fractions (<3 kDa) derived from the permeate resulted in three peptide subfractions. The subfraction with the lowest molecular weight demonstrated the most significant glucose uptake activity ( p ≤ 0.0001), maintaining its potency even at a dilution of 1:500 ( p ≤ 0.01).
References: J Nutr. 2005 Sep;135(9):2103-8. (PMID: 16140883)
Biochem Biophys Res Commun. 1973 May 1;52(1):115-20. (PMID: 4712181)
Clin Sci (Lond). 2009 Nov 23;118(5):315-32. (PMID: 19922415)
PLoS One. 2013 Aug 30;8(8):e71134. (PMID: 24023607)
Eur J Prev Cardiol. 2023 Sep 6;30(12):1193-1194. (PMID: 37158487)
Biomed J. 2017 Oct;40(5):257-262. (PMID: 29179880)
Food Chem. 2017 Mar 1;218:396-405. (PMID: 27719926)
J Endocrinol. 2006 Oct;191(1):159-70. (PMID: 17065399)
Int J Mol Sci. 2021 Aug 10;22(16):. (PMID: 34445300)
Am J Physiol Cell Physiol. 2020 Mar 1;318(3):C615-C626. (PMID: 31825657)
Diabetes Metab Res Rev. 2022 Nov;38(8):e3572. (PMID: 36001650)
Membranes (Basel). 2021 Jul 14;11(7):. (PMID: 34357178)
Food Funct. 2019 Mar 20;10(3):1619-1628. (PMID: 30821796)
Int J Mol Sci. 2022 Nov 16;23(22):. (PMID: 36430616)
Mar Drugs. 2023 Apr 28;21(5):. (PMID: 37233469)
Eur J Nutr. 2020 Apr;59(3):1013-1029. (PMID: 30972484)
J Agric Food Chem. 2019 Apr 3;67(13):3679-3690. (PMID: 30854852)
Mar Drugs. 2022 Aug 15;20(8):. (PMID: 36005524)
Food Sci Nutr. 2019 Apr 15;7(5):1848-1856. (PMID: 31139399)
Curr Res Food Sci. 2021 Mar 06;4:141-149. (PMID: 33778774)
Exp Diabetes Res. 2012;2012:789174. (PMID: 22701472)
J Clin Endocrinol Metab. 2014 Sep;99(9):E1713-20. (PMID: 24955608)
Food Funct. 2018 Jan 24;9(1):407-416. (PMID: 29218344)
Food Chem X. 2022 Feb 02;13:100222. (PMID: 35498998)
Int J Mol Sci. 2016 Jun 16;17(6):. (PMID: 27322241)
J Agric Food Chem. 2016 Feb 3;64(4):831-9. (PMID: 26758401)
Diabetologia. 2016 Apr;59(4):673-8. (PMID: 26868492)
J Vis Exp. 2017 Jun 25;(124):. (PMID: 28671646)
Clin Exp Immunol. 1993 Aug;93(2):273-8. (PMID: 8348756)
Food Funct. 2017 Jun 21;8(6):2249-2257. (PMID: 28534590)
Dis Model Mech. 2009 May-Jun;2(5-6):231-7. (PMID: 19407331)
Mar Drugs. 2021 Aug 25;19(9):. (PMID: 34564142)
Nutr Metab (Lond). 2016 Dec 9;13:92. (PMID: 27990172)
Cancer Sci. 2010 May;101(5):1073-9. (PMID: 20345478)
J Nutr Sci Vitaminol (Tokyo). 2009 Feb;55(1):81-6. (PMID: 19352067)
Neurochem Res. 2020 Jul;45(7):1481-1491. (PMID: 32314178)
Food Chem. 2014 Mar 15;147:124-30. (PMID: 24206695)
Cardiovasc Diabetol. 2018 Aug 31;17(1):122. (PMID: 30170598)
Int J Mol Sci. 2021 Sep 01;22(17):. (PMID: 34502417)
J Pharm Pharmacol. 2005 Dec;57(12):1575-80. (PMID: 16354401)
Food Res Int. 2020 Jul;133:109161. (PMID: 32466942)
Food Res Int. 2018 Apr;106:598-606. (PMID: 29579965)
Pharmaceuticals (Basel). 2024 Mar 01;17(3):. (PMID: 38543114)
Foods. 2020 Jun 29;9(7):. (PMID: 32610520)
Nutrients. 2022 Oct 14;14(20):. (PMID: 36296965)
Food Res Int. 2020 May;131:108989. (PMID: 32247474)
Mar Drugs. 2023 Feb 23;21(3):. (PMID: 36976193)
Food Chem. 2020 Oct 30;328:127096. (PMID: 32485583)
Food Chem. 2022 Dec 15;397:133821. (PMID: 35917789)
PLoS One. 2012;7(10):e45012. (PMID: 23056189)
J Agric Food Chem. 2012 Feb 1;60(4):973-8. (PMID: 22225496)
Int J Mol Sci. 2019 Oct 20;20(20):. (PMID: 31635140)
Int J Hypertens. 2019 Aug 5;2019:2345042. (PMID: 31467699)
J Food Sci. 2018 Jan;83(1):6-16. (PMID: 29227526)
Nat Rev Endocrinol. 2014 May;10(5):293-302. (PMID: 24663222)
Cells. 2022 Apr 12;11(8):. (PMID: 35455991)
فهرسة مساهمة: Keywords: DPP-IV inhibition; bioactive peptides; glucoregulatory peptides; glucose uptake; marine protein hydrolysate; metabolic disease; salmon protein hydrolysate
المشرفين على المادة: 0 (Dipeptidyl-Peptidase IV Inhibitors)
0 (Protein Hydrolysates)
IY9XDZ35W2 (Glucose)
EC 3.4.14.5 (Dipeptidyl Peptidase 4)
0 (Hypoglycemic Agents)
0 (Fish Proteins)
تواريخ الأحداث: Date Created: 20240426 Date Completed: 20240426 Latest Revision: 20240429
رمز التحديث: 20240429
مُعرف محوري في PubMed: PMC11050766
DOI: 10.3390/md22040151
PMID: 38667768
قاعدة البيانات: MEDLINE
الوصف
تدمد:1660-3397
DOI:10.3390/md22040151